Welcome to our dedicated page for Viridian Therapeutics SEC filings (Ticker: VRDN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Viridian Therapeutics, Inc. (Nasdaq: VRDN) SEC filings page on Stock Titan provides structured access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Viridian is a Waltham, Massachusetts-based biopharmaceutical company focused on antibody-based medicines for serious and rare diseases, including thyroid eye disease (TED) and autoimmune conditions involving IGF‑1R, TSHR, and FcRn pathways. Its common stock is registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Stock Market LLC under the symbol VRDN, as noted in multiple Form 8‑K filings.
Through this page, users can review current and historical Forms 8‑K in which Viridian reports material events such as clinical and regulatory milestones, collaboration and license agreements, financing transactions, and governance matters. Examples disclosed in recent 8‑K filings include public equity offerings, a royalty financing agreement, an amended credit facility, and the collaboration and license agreement with Kissei Pharmaceutical Co., Ltd. for veligrotug and VRDN‑003 in Japan. Other 8‑Ks furnish press releases reporting quarterly financial results and cash positions, providing insight into the company’s operating expenses, research and development investments, and capital resources.
Investors can also use the filings page to track capital markets activity and share-related arrangements, such as underwriting agreements for public offerings, equity incentive plan amendments, and employee stock purchase plans, all of which appear in Viridian’s current reports and proxy-related disclosures. These documents outline how the company structures its financing, equity compensation, and shareholder approvals as it advances late-stage TED programs and its FcRn inhibitor portfolio.
Stock Titan enhances this information by pairing real-time EDGAR updates with AI-powered summaries that highlight the key points of lengthy filings. Instead of reading entire documents line by line, users can quickly understand the main terms of material agreements, the significance of clinical and regulatory announcements, and the implications of financing transactions for Viridian’s runway and strategic plans. For deeper analysis, investors can drill down into specific filings—such as 10‑K annual reports, 10‑Q quarterly reports, and Form 4 insider transaction reports when available—to examine risk factors, detailed financial statements, and any reported insider buying or selling activity related to VRDN.
Viridian Therapeutics Chief Financial Officer files an amended insider transaction report reflecting tax-related share withholding. On the corrected Form 4/A, Seth Harmon is shown disposing of 2,031 shares of Viridian common stock on March 3, 2026 at $30.19 per share to cover tax obligations. Following this tax-withholding disposition, he beneficially owns 7,850 shares of common stock. The amendment updates both the number of shares and the price used to satisfy taxes, as well as the resulting total holdings, compared with the initial Form 4 filed on March 4, 2026.
Viridian Therapeutics Chief Operating Officer Thomas W. Beetham filed an amended insider report updating a prior Form 4. The amendment corrects the number of shares and price involved in a tax-withholding disposition of 3,048 shares of common stock at $30.19 per share on a transaction coded “F.”
These shares were withheld to cover taxes, rather than sold in an open-market trade. After this correction and all transactions reported in the original Form 4, Beetham is shown as beneficially owning 13,361 shares of Viridian Therapeutics common stock directly.
Viridian Therapeutics Chief Legal Officer updates prior tax-related share filing. Jennifer Tousignant filed an amended Form 4 to correct the number of shares and price previously reported as disposed to cover taxes. The amendment now shows a tax-withholding disposition of 1,675 shares of common stock at $30.19 per share on March 3, 2026, leaving her with 3,494 shares of Viridian Therapeutics common stock held directly.
Viridian Therapeutics President and CEO Stephen F. Mahoney disposed of 7,408 shares of common stock on March 3, 2026 at $30.19 per share to cover taxes. This amended Form 4 corrects the share and price figures previously reported and shows he beneficially owns 33,349 shares afterward.
Viridian Therapeutics’ Chief Legal Officer Jennifer Tousignant reported multiple equity compensation transactions. On
On
Viridian Therapeutics Chief Financial Officer Seth Harmon reported multiple equity compensation moves. On March 2, 2026 he received a stock option covering 102,850 shares and 20,550 restricted stock units, each at a stated price of $0.00 per share. On March 3, 2026, 6,267 RSUs converted into common stock and 2,091 shares of common stock were withheld at $29.32 per share to cover taxes, leaving him with 7,790 common shares held directly.
Viridian Therapeutics’ Chief Financial Officer Seth Harmon filed an amended Form 4 to correct his reported share ownership. The amendment explains that a prior Form 4 filed on March 4, 2025 inadvertently omitted 1,711 shares purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan.
After reflecting these previously purchased shares, Harmon is shown as directly beneficially owning 1,711 shares of Viridian Therapeutics common stock. The filing does not report any new transactions, but updates the accuracy of his disclosed holdings.
Viridian Therapeutics, Inc. officer Jennifer Tousignant filed an amended Form 4 to correct her reported holdings. The prior filing inadvertently left out 610 shares that were purchased under the Viridian Therapeutics, Inc. 2016 Employee Stock Purchase Plan. After this correction, she is shown as directly owning 610 common shares.
Viridian Therapeutics Chief Operating Officer Thomas W. Beetham reported multiple equity award transactions. On March 2, 2026, he received a stock option grant for 176,550 shares vesting in 48 equal monthly installments, and 35,300 Restricted Stock Units (RSUs) vesting 25% annually over four years.
On March 3, 2026, 9,409 RSUs converted into the same number of common shares, and 3,138 common shares were disposed of at
Viridian Therapeutics President and CEO Stephen F. Mahoney reported multiple equity award transactions. On March 2, 2026, he was granted stock options for 559,600 shares that vest in 48 equal monthly installments after the grant date, and 111,900 restricted stock units (RSUs) that vest in four annual installments starting March 2, 2026.
On March 3, 2026, 18,357 RSUs converted into an equal number of common shares as part of a prior grant that vests annually from March 3, 2025. To cover tax obligations, 7,627 common shares were disposed of at $29.32 per share through tax withholding, leaving 33,130 common shares held directly.